TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25081728

Group type: EXPERIMENTAL
Intervention: Hepatectomy combined with 'Jianpi Huayu Therapy' (treatment group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hepatectomy alone (control group)
Number of subjects: 120
Study: 22537179

Group type: EXPERIMENTAL
Intervention: Intensive intervention (Partner Schools)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Less intensive intervention (Associate Schools)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Comparison group with delayed intervention
Number of subjects: 58
Study: 19864968

Group type: EXPERIMENTAL
Intervention: Ceftriaxone treatment post-implementation of clinical practice guideline (CPG)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Ceftriaxone treatment pre-implementation of clinical practice guideline (CPG)
Number of subjects: 127
Study: 17453330

Group type: EXPERIMENTAL
Intervention: Negative thinking
Number of subjects: 52
Study: 15173671

Group type: EXPERIMENTAL
Intervention: Qigong training program (30 minutes daily for one month)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study: 11566656

Group type: EXPERIMENTAL
Intervention: Dairy product consumption >2.5 servings daily
Number of subjects: 20885

Group type: EXPERIMENTAL
Intervention: Calcium intake >600 mg/d from dairy products
Number of subjects: 20885

Group type: EXPERIMENTAL
Intervention: Skim milk consumption >600 mg Ca/d
Number of subjects: 20885
Study: 9445231

Group type: EXPERIMENTAL
Intervention: Octreotide, 100 microg TID SQ for 5 days after transplant (n = 10)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No additional treatment (Control group, n = 7)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Octreotide treatment (n = 10)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 17
Study: 7987998

Group type: EXPERIMENTAL
Intervention: Carboplatin (400 mg/m2 per day) combined with cyclophosphamide (1500 mg/m2 per day), thiotepa (120 mg/m2 per day), and mesna (3 g/day) for 4 consecutive days
Number of subjects: 9
Study: 2729934

Group type: COMPARATOR
Intervention: Ocular administration of recombinant alpha interferon; dosages not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group); details not specified.
Number of subjects: 0
Study: 5336037

Group type: EXPERIMENTAL
Intervention: Chloroquine treatment
Number of subjects: 0
Study: 31115192

Group type: EXPERIMENTAL
Intervention: Routine supportive care plus CIM intervention (nurse-led supportive care intervention using Complementary and Integrative Medicine)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Routine care alone (control group)
Number of subjects: 251
Study: 28323725

Group type: EXPERIMENTAL
Intervention: Oral insertion
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nasal insertion
Number of subjects: 66
Study: 25938633

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/d
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 23890686

Group type: EXPERIMENTAL
Intervention: Ecologically‐Based Treatment (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (n=30)
Number of subjects: 60
Study: 21418868

Group type: EXPERIMENTAL
Intervention: IORT plus internal drainage or laparotomy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (internal drainage or laparotomy only)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: IORT
Number of subjects: 65
Study: 19747427

Group type: EXPERIMENTAL
Intervention: Vitamin A (240 mg in four doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17760317

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance levels in psychotherapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Local rupture-and-repair patterns
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Linear trends in alliance ratings
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Global high-low-high pattern
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Treatment differences
Number of subjects: 44
Study: 15202379

Group type: EXPERIMENTAL
Intervention: 16.5 g of Minolest®
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 15061347

Group type: EXPERIMENTAL
Intervention: Manual-assisted cognitive behavior therapy (MACT)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: MACT
Number of subjects: 480
Study: 10465667

Group type: EXPERIMENTAL
Intervention: Mirror intervention placed on the right side of the patient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirror intervention placed in the coronal position with objects behind the head
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mirror intervention
Number of subjects: 0
Study: 7495235

Group type: EXPERIMENTAL
Intervention: Aspirin plus vitamin E [0.4 g (400 IU)/d; n = 52]
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aspirin alone (325 mg; n = 48)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Aspirin plus vitamin E
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 100
Study: 2044754

Group type: EXPERIMENTAL
Intervention: Inpatient Family Intervention (IFI)
Number of subjects: 169
Study: 7011250

Group type: EXPERIMENTAL
Intervention: Pemoline (noneuphorigenic psychostimulant drug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pemoline (for subgroup with parents describing them in the 95th percentile of childhood hyperactivity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (for subgroup with parents describing them in the 95th percentile of childhood hyperactivity)
Number of subjects: 0
Study: 31075364

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 29452372

Group type: EXPERIMENTAL
Intervention: Maternal influenza vaccination at 17-25 weeks gestation
Number of subjects: 3646

Group type: EXPERIMENTAL
Intervention: Maternal influenza vaccination at 26-34 weeks gestation
Number of subjects: 3646

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3646
Study: 27312203

Group type: EXPERIMENTAL
Intervention: DMARD combinations or biologic agents
Number of subjects: 672

Group type: COMPARATOR
Intervention: Methotrexate monotherapy or steroid and DMARD combinations
Number of subjects: 672
Study: 25227564

Group type: EXPERIMENTAL
Intervention: L-lysine (6 g/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 22428809

Group type: EXPERIMENTAL
Intervention: MI+HealthCall
Number of subjects: 33

Group type: COMPARATOR
Intervention: MI-only
Number of subjects: 33
Study: 20023571

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted agents (e.g., receptor tyrosine kinase inhibitors)
Number of subjects: 0
Study: 18058408

Group type: EXPERIMENTAL
Intervention: Naltrexone alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open label disulfiram and naltrexone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open label disulfiram and placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 0
Study: 16131600

Group type: EXPERIMENTAL
Intervention: GH therapy (1.2 IU/day for men and 1.8 IU/day for women)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 11957004

Group type: EXPERIMENTAL
Intervention: FloSealTM Matrix (FM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gelfoam(R) plus thrombin (GT)
Number of subjects: 0
Study: 10423715

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Estradiol valerate/cyproterone acetate (EV/CPA)
Number of subjects: 104
Study: 7474008

Group type: EXPERIMENTAL
Intervention: Artificial neural network prediction
Number of subjects: 580
Study: 31679924

Group type: EXPERIMENTAL
Intervention: Finger Kazoo Intensive Short-Term Vocal Therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 31377056

Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Number of subjects: 2185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185
Study: 28877893

Group type: EXPERIMENTAL
Intervention: Bifidobacteria-supplemented formula (107 CFU/g of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, B. longum subspecies infantis)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control formula without bifidobacteria (placebo)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Breast milk (breastfed controls)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Infants birthed vaginally
Number of subjects: 106
Study: 25052624

Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Comparison group (books about bereavement)
Number of subjects: 244
Study: 23239675

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 21684151

Group type: EXPERIMENTAL
Intervention: Amrubicin alone (A) 45mg/m² i.v. days 1-3
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cisplatin combined with amrubicin (PA) 60mg/m² i.v. day 1 and 40mg/m² i.v. days 1-3
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cisplatin combined with etoposide (PE) 75mg/m² i.v. day 1 and 100mg/m² days 2-3
Number of subjects: 99
Study: 19809347

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) for 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo inspiratory muscle training (P-IMT) for 12 weeks
Number of subjects: 32
Study: 16938697

Group type: EXPERIMENTAL
Intervention: Recognition of countries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free-recall task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contiguity in free-recall output
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responses in a free-association task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prediction of recall from recognition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: News mentions of countries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative prosperity, population density, geographic area of countries
Number of subjects: 0
Study: 15373937

Group type: EXPERIMENTAL
Intervention: 150 mg aliskiren
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10949098

Group type: EXPERIMENTAL
Intervention: Relaxation (imagery‐based relaxation tape)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stress (Stroop test)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (video)
Number of subjects: 50
Study: 9302482

Group type: EXPERIMENTAL
Intervention: Isometric strength training (strength)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Isometric strength combined with flexibility training (strength and flexibility)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 8346829

Group type: EXPERIMENTAL
Intervention: Sheridan design tube
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mallinckrodt design tube
Number of subjects: 48

Group type: COMPARATOR
Intervention: Rusch design tube
Number of subjects: 48
Study: 3538593

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 161

Group type: COMPARATOR
Intervention: Adriamycin chemotherapy
Number of subjects: 161
Study: 31735242

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Motivational Interviewing integrated with Cognitive-Behavioral Therapy (MI-CBT)
Number of subjects: 85
Study: 28040753

Group type: EXPERIMENTAL
Intervention: Group I (no to 1 occlusion)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Study population
Number of subjects: 233
Study: 25886254

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg modified-release capsules for 12 months
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo capsules for 12 months
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 226
Study: 24210673

Group type: EXPERIMENTAL
Intervention: PRIMAS
Number of subjects: 160

Group type: COMPARATOR
Intervention: CG
Number of subjects: 160
Study: 21521720

Group type: EXPERIMENTAL
Intervention: Highlighting relatedness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Writing about relatedness experiences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relatedness manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral task
Number of subjects: 0
Study: 18520291

Group type: EXPERIMENTAL
Intervention: Novel agents in lung cancer treatment
Number of subjects: 0
Study: 16159704

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (group 1)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Periprostatic lidocaine injection (group 2)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No anesthetic (group 3)
Number of subjects: 93
Study: 12653258

Group type: EXPERIMENTAL
Intervention: OPC‐31260 30 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Furosemide 20 mg (F)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg plus OPC‐31260 30 mg (O+F)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OPC‐31260 30 mg (O)
Number of subjects: 12
Study: 10755239

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg/week
Number of subjects: 782

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 782
Study: 8874907

Group type: EXPERIMENTAL
Intervention: 80 micrograms. kg‐1 morphine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 4 micrograms. kg‐1 buprenorphine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 8 micrograms. kg‐1 buprenorphine
Number of subjects: 120
Study: 1576284

Group type: EXPERIMENTAL
Intervention: Metronidazole (dosage regimens not specified)
Number of subjects: 50
Study: 3888491

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 45
Study: 31353413

Group type: EXPERIMENTAL
Intervention: Working Memory (WM) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: General knowledge training
Number of subjects: 0
Study: 29730013

Group type: EXPERIMENTAL
Intervention: Decision-making preference scores
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Higher decision-making preference scores
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Information-seeking preference scores
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Asthma control test scores, spirometry values, and health care use
Number of subjects: 189
Study: 28851314

Group type: EXPERIMENTAL
Intervention: Arm A (4 weeks of oral S-1 and a 2-week rest over 12 months)
Number of subjects: 78
Study: 26574829

Group type: EXPERIMENTAL
Intervention: Braun jejunojejunostomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard Whipple procedure
Number of subjects: 30
Study: 23229932

Group type: EXPERIMENTAL
Intervention: Postdilution OL-HDF
Number of subjects: 782

Group type: COMPARATOR
Intervention: High-flux HD
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: High-efficiency OL-HDF (subgroup with median substitution volume >17.4 L per session)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: High-efficiency OL-HDF
Number of subjects: 782
Study: 21508750

Group type: EXPERIMENTAL
Intervention: Early insertion (1-3 days postpartum)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard insertion (4-8 weeks postpartum)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Early insertion
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard insertion
Number of subjects: 69
Study: 18586462

Group type: EXPERIMENTAL
Intervention: 20 mg of Zn supplementation (as Zn sulfate)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 16862245

Group type: EXPERIMENTAL
Intervention: Levomepromazine (LMP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Chlorpromazine (CPZ)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Haloperidol (HAL)
Number of subjects: 38
Study: 15146420

Group type: COMPARATOR
Intervention: Diet plus exercise
Number of subjects: 316

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 316

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 316

Group type: COMPARATOR
Intervention: Weight-loss groups (diet and diet plus exercise)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Joint space width
Number of subjects: 316
Study: 11235596

Group type: EXPERIMENTAL
Intervention: Optical imaging method with acetic acid application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optical imaging method
Number of subjects: 0
Study: 9451749

Group type: EXPERIMENTAL
Intervention: Continuing pain education program for surgical cancer nurses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8166893

Group type: EXPERIMENTAL
Intervention: morphine/bupivacaine
Number of subjects: 38

Group type: COMPARATOR
Intervention: saline
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: morphine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: bupivacaine
Number of subjects: 38
Study: 3137764

Group type: EXPERIMENTAL
Intervention: Midazolam/alfentanil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiopentone/alfentanil/nitrous oxide
Number of subjects: 0
Study: 31022103

Group type: EXPERIMENTAL
Intervention: Hand width at 120% of biacromial width
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hand width at 170% of biacromial width
Number of subjects: 10
Study: 30328056

Group type: EXPERIMENTAL
Intervention: Combined smoking cessation and pain management intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 30
Study: 27655646

Group type: EXPERIMENTAL
Intervention: 5 mg/kg thiamylal
Number of subjects: 48

Group type: COMPARATOR
Intervention: 1.5 mg/kg propofol
Number of subjects: 48
Study: 24656609

Group type: EXPERIMENTAL
Intervention: 150 mg or 300 mg subcutaneous daclizumab HYP every 4 weeks for 52 weeks (treatment initiation group)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Continuous treatment with daclizumab HYP (no washout)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Washout and re-initiation group (300 mg daclizumab HYP)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Continuous treatment group
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Treatment initiation group
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Washout and re-initiation group
Number of subjects: 517
Study: 21525406

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with cisplatin 75 mg/m(2), epirubicin 75 mg/m(2) and paclitaxel (Taxol) 175 mg/m(2) (CEP) followed by concomitant radiotherapy (RT) and weekly cisplatin 40 mg/m(2)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Concomitant chemoradiotherapy (CCRT) alone
Number of subjects: 141
Study: 21029664

Group type: EXPERIMENTAL
Intervention: Surgery combined with chemotherapy (4-6 cycles of etoposide + cisplatin or carboplatin)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-surgery chemotherapy (6 cycles of etoposide + cisplatin or carboplatin)
Number of subjects: 37
Study: 18221449

Group type: EXPERIMENTAL
Intervention: Relaxation (R)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Quiet Sitting (QS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: GAD patients
Number of subjects: 49
Study: 15925449

Group type: EXPERIMENTAL
Intervention: Individually tailored follow-up sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group follow-up sessions
Number of subjects: 0
Study: 14693901

Group type: EXPERIMENTAL
Intervention: Smart Hockey video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control teams
Number of subjects: 0
Study: 10969262

Group type: EXPERIMENTAL
Intervention: Children with rickets
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control children
Number of subjects: 123
Study: 8791030

Group type: EXPERIMENTAL
Intervention: 311C90 20 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1732975

Group type: EXPERIMENTAL
Intervention: MR imaging of the TMJ
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 32
Study: 6428555

Group type: EXPERIMENTAL
Intervention: Consultation with a clinical psychologist in addition to usual primary care management
Number of subjects: 2

Group type: COMPARATOR
Intervention: Usual primary care management
Number of subjects: 2
Study: 31504535

Group type: EXPERIMENTAL
Intervention: Transatrial approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transventricular approach
Number of subjects: 0
Study: 29971581

Group type: EXPERIMENTAL
Intervention: With-drain
Number of subjects: 66

Group type: COMPARATOR
Intervention: No-drain
Number of subjects: 66
Study: 26908330

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 471

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 471
Study: 25123656

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) alone
Number of subjects: 1129
Study: 22519849

Group type: EXPERIMENTAL
Intervention: Remifentanil during recovery from propofol anaesthesia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Remifentanil during recovery from sevoflurane anaesthesia
Number of subjects: 74
Study: 21235068

Group type: EXPERIMENTAL
Intervention: EA + cupping
Number of subjects: 128

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 128
Study: 18203907

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified complementary food (FCF), Mi Papilla, consumed over 11 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (same-age children in nearby communities eligible for the program 1 year later).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PANN 2000 children (older subgroup 12-14 months at program start).
Number of subjects: 0